<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04933760</url>
  </required_header>
  <id_info>
    <org_study_id>CV-CLN-007</org_study_id>
    <nct_id>NCT04933760</nct_id>
  </id_info>
  <brief_title>CV-SQuISH-ED: Clinical Validation Study</brief_title>
  <official_title>CV-SQuISH-ED: A Clinical Validation Solving the Question of Inflammation or Sepsis Hastily in the Emergency Department</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytovale, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytovale, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the diagnostic performance of the investigational Cytovale System&#xD;
      &amp; IntelliSep Test as a diagnostic marker of sepsis in a population of patients presenting to&#xD;
      the emergency department with signs or suspicion of infection compared to retrospective&#xD;
      physician adjudication, per the sepsis 3 definition, of those patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-site prospective study to evaluate the diagnostic performance of the&#xD;
      investigational Cytovale System &amp; IntelliSep Test for patients presenting to the Emergency&#xD;
      Department with signs or suspicion of infection. The IntelliSep Test is a microfluidic test&#xD;
      that measures the biophysical properties of human leukocytes in conjunction with other&#xD;
      laboratory findings and clinical assessments to aid in the early detection of sepsis with&#xD;
      organ dysfunction occurring within the first three days after the blood sample collection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 18, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>IntelliSep Index versus Retrospective Physician Diagnosis (RPD) per the sepsis 3 definition</measure>
    <time_frame>30 days</time_frame>
    <description>To validate the diagnostic performance of the investigational Cytovale System &amp; IntelliSep Test as a diagnostic marker of sepsis in a population of patients presenting to the emergency department with signs or suspicion of infection, the IntelliSep test score is compared to the non-reference method of retrospective physician adjudication, per the sepsis 3 definition, of those patients.</description>
  </primary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Sepsis</condition>
  <condition>Infection</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cytovale IntellipSep test</intervention_name>
    <description>The Cytovale IntelliSep test measures a series of physical properties that indicate activation of leukocytes obtained from a venous K2-EDTA anti-coagulated whole blood sample.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients presenting to the Emergency Department with signs or suspicion of infection.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ≥ 18 years old&#xD;
&#xD;
          2. The first vital sign (any one of: blood pressure, temperature, pulse or respiratory&#xD;
             rate) has been recorded in the medical record&#xD;
&#xD;
          3. A 300µl blood sample originally collected in a K2 EDTA (hematology purple top) tube&#xD;
             within 4 hours of the first recorded vital sign is available.&#xD;
&#xD;
          4. Sign or suspicion of infection, defined as meeting either of criterion A-1 and A-2&#xD;
             (based on temperature, WBC, heart rate, respiratory rate and/or culture order&#xD;
             criteria):&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients in whom a palliative care or hospice course is expected during ED visit&#xD;
&#xD;
          2. Self-reported, documented or otherwise known to be actively enrolled on any&#xD;
             experimental/investigational therapeutic medication prior to blood collection&#xD;
&#xD;
          3. Self-reported, documented, or known history of a hematologic malignancy (any leukemia,&#xD;
             lymphoma, or myeloma), myelodysplastic syndrome, or myeloproliferative disorder&#xD;
&#xD;
          4. Self-reported, documented or otherwise known to receive a chemotherapeutic agent or&#xD;
             other excluded medication in the past 3 months (Appendix C)&#xD;
&#xD;
          5. Self-reported, documented or otherwise known to have undergone a hematopoietic stem&#xD;
             cell transplant or any solid organ transplant&#xD;
&#xD;
          6. Patients transferred to the Emergency Department from another acute care facility&#xD;
&#xD;
          7. Residents or patients of a hospital-based skilled nursing facility&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tonya Jagneaux, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lady of the Lake Regional Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hariharan Regunath, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Missouri-Columbia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Henning, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Simon Mahler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lady of the Lake Regional Medical Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>June 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2021</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

